Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours.

Michele Caraglia, Raffaele Addeo, Raffaele Costanzo, Liliana Montella, Vincenzo Faiola, Monica Marra, Alberto Abbruzzese, Giovannella Palmieri, Alfredo Budillon, Francesco Grillone, Salvatore Venuta, Pierosandro Tagliaferri, Salvatore Del Prete

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

OBJECTIVE: A combination regimen of temozolomide (TMZ) and pegylated liposomal doxorubicin has been evaluated in the treatment of brain metastases from solid tumours. STUDY DESIGN: Nineteen consecutive patients (pts) have been enrolled in a prospective phase II trial and treated with TMZ 200 mg/m2 (days 1-5) and pegylated liposomal doxorubicin 35 mg/m2 (day 1) every 28 days. The study was prospectively projected according to the Simon's two-stage optimal design. RESULTS: Major toxicities have been grade III neutropenia and thrombocytopenia in one patient (pt) and grade III erythrodisesthesia in two pts. Three pts achieved a complete response (CR) and four a partial response (PR), for an overall response rate of 36.8% (95% CI: 19.1-59.2), which exceeded the target activity in the study design. A significant improvement in quality of life was demonstrated by FACT-G analysis. The median Progression Free Survival (PFS) was 5.5 (95% CI: 2.7-8.2) months while the median Overall Survival (OS) was 10.0 months (95% CI: 6.3-13.7). CONCLUSIONS: The TMZ/pegylated liposomal doxorubicin regimen was well tolerated with an encouraging activity in brain metastases from solid tumours.

Original languageEnglish
Pages (from-to)34-39
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume57
Issue number1
Publication statusPublished - Jan 2006

Fingerprint

temozolomide
Tumors
Brain
Neoplasm Metastasis
Neoplasms
Toxicity
Therapeutics
Neutropenia
Thrombocytopenia
Disease-Free Survival
Quality of Life
Survival
liposomal doxorubicin

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. / Caraglia, Michele; Addeo, Raffaele; Costanzo, Raffaele; Montella, Liliana; Faiola, Vincenzo; Marra, Monica; Abbruzzese, Alberto; Palmieri, Giovannella; Budillon, Alfredo; Grillone, Francesco; Venuta, Salvatore; Tagliaferri, Pierosandro; Del Prete, Salvatore.

In: Cancer Chemotherapy and Pharmacology, Vol. 57, No. 1, 01.2006, p. 34-39.

Research output: Contribution to journalArticle

Caraglia, M, Addeo, R, Costanzo, R, Montella, L, Faiola, V, Marra, M, Abbruzzese, A, Palmieri, G, Budillon, A, Grillone, F, Venuta, S, Tagliaferri, P & Del Prete, S 2006, 'Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours.', Cancer Chemotherapy and Pharmacology, vol. 57, no. 1, pp. 34-39.
Caraglia, Michele ; Addeo, Raffaele ; Costanzo, Raffaele ; Montella, Liliana ; Faiola, Vincenzo ; Marra, Monica ; Abbruzzese, Alberto ; Palmieri, Giovannella ; Budillon, Alfredo ; Grillone, Francesco ; Venuta, Salvatore ; Tagliaferri, Pierosandro ; Del Prete, Salvatore. / Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. In: Cancer Chemotherapy and Pharmacology. 2006 ; Vol. 57, No. 1. pp. 34-39.
@article{e3ecea34b158493eb9d071147e4993b3,
title = "Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours.",
abstract = "OBJECTIVE: A combination regimen of temozolomide (TMZ) and pegylated liposomal doxorubicin has been evaluated in the treatment of brain metastases from solid tumours. STUDY DESIGN: Nineteen consecutive patients (pts) have been enrolled in a prospective phase II trial and treated with TMZ 200 mg/m2 (days 1-5) and pegylated liposomal doxorubicin 35 mg/m2 (day 1) every 28 days. The study was prospectively projected according to the Simon's two-stage optimal design. RESULTS: Major toxicities have been grade III neutropenia and thrombocytopenia in one patient (pt) and grade III erythrodisesthesia in two pts. Three pts achieved a complete response (CR) and four a partial response (PR), for an overall response rate of 36.8{\%} (95{\%} CI: 19.1-59.2), which exceeded the target activity in the study design. A significant improvement in quality of life was demonstrated by FACT-G analysis. The median Progression Free Survival (PFS) was 5.5 (95{\%} CI: 2.7-8.2) months while the median Overall Survival (OS) was 10.0 months (95{\%} CI: 6.3-13.7). CONCLUSIONS: The TMZ/pegylated liposomal doxorubicin regimen was well tolerated with an encouraging activity in brain metastases from solid tumours.",
author = "Michele Caraglia and Raffaele Addeo and Raffaele Costanzo and Liliana Montella and Vincenzo Faiola and Monica Marra and Alberto Abbruzzese and Giovannella Palmieri and Alfredo Budillon and Francesco Grillone and Salvatore Venuta and Pierosandro Tagliaferri and {Del Prete}, Salvatore",
year = "2006",
month = "1",
language = "English",
volume = "57",
pages = "34--39",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours.

AU - Caraglia, Michele

AU - Addeo, Raffaele

AU - Costanzo, Raffaele

AU - Montella, Liliana

AU - Faiola, Vincenzo

AU - Marra, Monica

AU - Abbruzzese, Alberto

AU - Palmieri, Giovannella

AU - Budillon, Alfredo

AU - Grillone, Francesco

AU - Venuta, Salvatore

AU - Tagliaferri, Pierosandro

AU - Del Prete, Salvatore

PY - 2006/1

Y1 - 2006/1

N2 - OBJECTIVE: A combination regimen of temozolomide (TMZ) and pegylated liposomal doxorubicin has been evaluated in the treatment of brain metastases from solid tumours. STUDY DESIGN: Nineteen consecutive patients (pts) have been enrolled in a prospective phase II trial and treated with TMZ 200 mg/m2 (days 1-5) and pegylated liposomal doxorubicin 35 mg/m2 (day 1) every 28 days. The study was prospectively projected according to the Simon's two-stage optimal design. RESULTS: Major toxicities have been grade III neutropenia and thrombocytopenia in one patient (pt) and grade III erythrodisesthesia in two pts. Three pts achieved a complete response (CR) and four a partial response (PR), for an overall response rate of 36.8% (95% CI: 19.1-59.2), which exceeded the target activity in the study design. A significant improvement in quality of life was demonstrated by FACT-G analysis. The median Progression Free Survival (PFS) was 5.5 (95% CI: 2.7-8.2) months while the median Overall Survival (OS) was 10.0 months (95% CI: 6.3-13.7). CONCLUSIONS: The TMZ/pegylated liposomal doxorubicin regimen was well tolerated with an encouraging activity in brain metastases from solid tumours.

AB - OBJECTIVE: A combination regimen of temozolomide (TMZ) and pegylated liposomal doxorubicin has been evaluated in the treatment of brain metastases from solid tumours. STUDY DESIGN: Nineteen consecutive patients (pts) have been enrolled in a prospective phase II trial and treated with TMZ 200 mg/m2 (days 1-5) and pegylated liposomal doxorubicin 35 mg/m2 (day 1) every 28 days. The study was prospectively projected according to the Simon's two-stage optimal design. RESULTS: Major toxicities have been grade III neutropenia and thrombocytopenia in one patient (pt) and grade III erythrodisesthesia in two pts. Three pts achieved a complete response (CR) and four a partial response (PR), for an overall response rate of 36.8% (95% CI: 19.1-59.2), which exceeded the target activity in the study design. A significant improvement in quality of life was demonstrated by FACT-G analysis. The median Progression Free Survival (PFS) was 5.5 (95% CI: 2.7-8.2) months while the median Overall Survival (OS) was 10.0 months (95% CI: 6.3-13.7). CONCLUSIONS: The TMZ/pegylated liposomal doxorubicin regimen was well tolerated with an encouraging activity in brain metastases from solid tumours.

UR - http://www.scopus.com/inward/record.url?scp=33644691816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644691816&partnerID=8YFLogxK

M3 - Article

VL - 57

SP - 34

EP - 39

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 1

ER -